Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | Director | December 31, 2019 | January 03, 2020 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | COO & Head of Corp.Development | May 29, 2018 | June 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date December 31, 2019 · Filed January 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,887 |
Ending reported balance
After 2019-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-12-31 · Grant · Acquired 31,780 · Balance 111,994 F1: 31,780 shares vest on 12/31/2020. Row 2 · 2019-12-31 · Tax withholding · Disposed 40,107 · Balance 71,887 F2: Represents shares withheld to satisfy withholding tax obligations upon the vesting of a restricted stock grant. |
Filing footnotes · ownership attribution and instrument terms
F1: 31,780 shares vest on 12/31/2020.
F2: Represents shares withheld to satisfy withholding tax obligations upon the vesting of a restricted stock grant.
Scholar Rock Holding Corp
Report date May 29, 2018 · Filed June 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.77 · Expires 2028-02-20 | Direct | 8,757 |
Reported balance
After 2018-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-29 · Grant · Acquired 8,757 · Balance 8,757 F1: This option vested in full upon the closing of the Issuer's initial public offering on May 29, 2018. The performance criteria for the entire option grant of 8,757 shares was met, resulting in the full vesting of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vested in full upon the closing of the Issuer's initial public offering on May 29, 2018. The performance criteria for the entire option grant of 8,757 shares was met, resulting in the full vesting of the option.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MARINUS PHARMACEUTICALS, INC.
Report date February 07, 2025 · Filed February 11, 2025
Section 16 reporting ended · disclosed 2025-02-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-07 · Disposition to issuer · Disposed 8,600 · Balance 2,300 F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Row 2 · 2025-02-11 · Disposition to issuer · Disposed 2,300 · Balance 0 F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F2: Represents 2,300 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2034-06-18 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-11 · Disposition to issuer · Disposed 10,450 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.74 · Expires 2034-01-18 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-11 · Disposition to issuer · Disposed 20,900 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2033-01-26 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-11 · Disposition to issuer · Disposed 16,200 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2032-02-04 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-11 · Disposition to issuer · Disposed 12,375 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.60 · Expires 2031-01-15 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-11 · Disposition to issuer · Disposed 16,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2029-12-11 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-11 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash.
F2: Represents 2,300 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2025 Filed Feb 11, 2025 09:19 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001104659-25-011248 · tm255946-10_4seq1.xml · derivative · entry 8 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2029-12-11 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:19 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0001104659-25-011248 · tm255946-10_4seq1.xml · derivative · entry 7 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires 2031-01-15 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:19 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,375 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001104659-25-011248 · tm255946-10_4seq1.xml · derivative · entry 6 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,375 shares Expires 2032-02-04 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:19 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,200 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001104659-25-011248 · tm255946-10_4seq1.xml · derivative · entry 5 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,200 shares Expires 2033-01-26 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:19 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $9.74 | $0.00 |
DisclosureSEC source: 0001104659-25-011248 · tm255946-10_4seq1.xml · derivative · entry 4 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,900 shares Expires 2034-01-18 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:19 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,450 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001104659-25-011248 · tm255946-10_4seq1.xml · derivative · entry 3 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,450 shares Expires 2034-06-18 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:19 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerCommon Stock | 2,300 | $0.55 | $1,265.00 |
DisclosureSEC source: 0001104659-25-011248 · tm255946-10_4seq1.xml · nonDerivative · entry 2 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F2 · shares: Represents 2,300 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. F1 · price: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 09:19 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerCommon Stock | 8,600 | $0.55 | $4,730.00 |
DisclosureSEC source: 0001104659-25-011248 · tm255946-10_4seq1.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,300 F1 · kind: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F1 · price: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:17 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | SaleCommon Stock | 1,600 | $0.54 | $864.00 |
DisclosureSEC source: 0001415889-25-001930 · form4-01232025_090128.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,900 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on March 10, 2024 to cover tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 16:23 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 10,450 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001415889-24-017634 · form4-06202024_080645.xml · derivative · entry 2 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,450 Underlying: Common Stock · 10,450 shares Expires 2034-06-18 F2 · derivative.exercise_date: The option vests and becomes exercisable in full on July 15, 2025, subject to the reporting person's continued service with the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 16:23 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017634 · form4-06202024_080645.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on July 15, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 16:26 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $9.74 | $0.00 |
DisclosureSEC source: 0001415889-24-001600 · form4-01192024_090126.xml · derivative · entry 2 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2034-01-18 F2 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on February 18, 2024, subject to the reporting person's continued service with the Issuer. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 16:26 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001600 · form4-01192024_090126.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,200 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on January 18, 2024, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 16:36 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | SaleCommon Stock | 750 | $6.56 | $4,920.00 |
DisclosureSEC source: 0001415889-23-002162 · form4-02082023_090232.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 plan to cover tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.55 - $6.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 16:26 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 16,200 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001415889-23-001560 · form4-01302023_090107.xml · derivative · entry 2 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2033-01-26 F2 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on February 26, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 16:26 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-001560 · form4-01302023_090107.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,350 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on January 26, 2024, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| February 04, 2022 Filed Feb 7, 2022 16:09 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 12,375 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001104659-22-012783 · tm225605-5_4seq1.xml · derivative · entry 2 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,375 Underlying: Common Stock · 12,375 shares Expires 2032-02-04 F2 · derivative.exercise_date: The option vests and becomes exercisable monthly over 12 months beginning on March 4, 2022. Read SEC document |
| February 04, 2022 Filed Feb 7, 2022 16:09 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-012783 · tm225605-5_4seq1.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on February 4, 2023, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 20:13 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 16,500 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0001104659-21-005519 · tm213599-5_4seq1.xml · derivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-01-15 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 12 equal monthly installments, commencing on 1/31/21. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:06 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 40,107 | $4.72 | $189,305.04 |
DisclosureSEC source: 0001209191-20-001171 · doc4.xml · nonDerivative · entry 2 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,887 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of a restricted stock grant. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:06 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 31,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001171 · doc4.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,994 F1 · shares: 31,780 shares vest on 12/31/2020. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 16:06 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001104659-19-072570 · a4.xml · derivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-12-11 F1 · derivative.exercise_date: Options to purchase shares of common stock vest monthly in 36 equal installments beginning 1/1/20. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:16 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 80,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-000587 · doc4.xml · nonDerivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,214 F1 · shares: 80,214 shares vest on 12/31/2019. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:15 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051785 · doc4.xml · derivative · entry 1 Ezickson Elan · CIK 0001486429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-09-18 F1 · derivative.exercise_date: 25,000 shares shall vest on each of 9/18/2019 and 9/18/2020. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 8,757 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0001104659-18-037314 · a4.xml · derivative · entry 1 Ezickson Elan · CIK 0001486429 · COO & Head of Corp.Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,757 Underlying: Common Stock · 8,757 shares Expires 2028-02-20 F1 · derivative.exercise_date: This option vested in full upon the closing of the Issuer's initial public offering on May 29, 2018. The performance criteria for the entire option grant of 8,757 shares was met, resulting in the full vesting of the option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.